Iofetamine

Summary

Iofetamine (CHEMBL1201308) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 303.18 Da · C12H18IN

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201308
Name	Iofetamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3729
Molecular formula	C12H18IN
Molecular weight	303.18
InChIKey	ISEHJSHTIVKELA-UHFFFAOYSA-N

SMILES: CC(C)NC(C)CC1=CC=C(C=C1)I

IUPAC name: 1-(4-iodophenyl)-N-propan-2-ylpropan-2-amine

Also known as: SID90341459, SID50111119

Parent form; salt/anhydrous children: CHEMBL1200360, CHEMBL1255865

Patent coverage: 97 distinct patent families (230 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).